Business Wire

VA-REGULA

7.3.2024 08:01:27 CET | Business Wire | Press release

Share
Regula Elevates ID Fraud Protection with Enhanced Liveness Checks

Liveness detection, both for individuals and their IDs, has become a cornerstone for a secure customer onboarding process. It is especially crucial in remote scenarios where document submission and verification are done via the Internet. With 65% of organizations globally relying on digital document checks in their online identity verification workflows, robust anti-fraud measures cannot be overrated.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240306499292/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Regula Document Reader SDK verifies the authenticity of an ID by checking its optically variable features (Photo: Business Wire)

Responding to this growing need for additional fraud protection, Regula has released an update for its Regula Document Reader SDK, a comprehensive solution for the most reliable and secure identity document verification. Thanks to improved neural networks, detecting and analyzing an identity document has become twice as fast. The software is now able to check dynamic security features that were previously eligible for verification in on-site scenarios only. These checks include, but are not limited to:

  • Optically Variable Ink (OVI), which changes color depending on the angle of observation and illumination;
  • Lenticular images, such as Multiple Laser Image (MLI) and Dynaprint, which consist of several initial images that appear depending on the angle of observation;
  • Holograms, which reflect and form an image in reflected light when changing the angle of observation and illumination.

The updated Regula Document Reader SDK can reliably validate the authenticity of an ID by verifying such optically variable features. The solution employs advanced algorithms to analyze the presence of these features and images in documents, as well as their exact location, their content, and their liveness—e.g., changing colors, images, etc.—based on a specific document template. All a user needs to do is show their ID in front of a smartphone camera, and the rest is technology. With advanced document liveness detection, Regula Document Reader SDK effectively prevents identity fraud and other types of fraud, such as printed photo attacks and screen replay attacks.

Apart from that, all the client-side data retrieved during liveness checks and verification sessions can be securely transferred in encrypted form to the backend client’s server. Captured document images, session video, RFID session data, document liveness session data, and other processing data can be used to re-process a verification session in a customer’s trusted environment. This “zero-trust-to-mobile” approach adds an important layer of trustworthiness to the verification process, as it ensures that no data is manipulated by fraudsters while being transferred from mobile devices.

“Today, a mere $15 is all it takes to get an AI-generated ID — a golden ticket to illicit banking and crypto operations, and to circumventing anti-money laundering protocols. Amid this digital wild west, the necessity for document liveness checks has never been more critical. They serve as an essential counter-fraud measure, preventing identity theft and document tampering. By ensuring that a real document is being presented during onboarding, you can significantly enhance the verification process to prove that it is genuine and not a counterfeit or digital replica. That’s why we never stop researching and improving the functionality of Regula Document Reader SDK,” says Ihar Kliashchou, Chief Technology Officer at Regula.

To learn more about the recent update of Regula Document Reader SDK, please visit the official webpage.

About Regula
With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies in document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security, or speed.

Regula was named a Representative Vendor in the Gartner® Market Guide for Identity Verification in 2023.

Learn more at regulaforensics.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240306499292/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vonage Expands Developer Ecosystem to Accelerate the Next Era of Enterprise Digital Transformation19.2.2026 10:08:00 CET | Press release

Vonage verified Postman workspace extends reach by 40+ million developers; MCP servers and Startup Program among resources designed to further accelerate time-to-value for developers and enterprises Vonage, part of Ericsson (NASDAQ: ERIC), today announced a number of new initiatives, to further expand and enable its global developer community. By growing its developer community and tools, giving developers and enterprises access to new mobile network insights and capabilities that can be embedded into existing applications and workflows, Vonage is accelerating its strategy to transform mobile networks into a programmable platform. Putting Vonage APIs in the Hands of 40 million+ More Developers Vonage is announcing the launch of its Verified Workspace on the Postman API Network, making Vonage APIs available to the 40+ million developers who use Postman. The new, verified workspace gives Postman’s community of global developer members certified access to Vonage’s portfolio of Network API

Brenus Pharma Presented New Preclinical and Early Clinical Data in Colorectal Cancer During AACR Immuno-Oncology Conference 202619.2.2026 08:50:00 CET | Press release

Brenus Pharma, a clinical-stage biotechnology company pioneering in vivo “off-the-shelf” immunotherapies, announced the selection of an abstract for a poster presentation at the American Association for Cancer Research Immuno-Oncology (AACRIO) annual conference (February 18-21, 2026), in Los Angeles. The poster showcases new preclinical data and early clinical insights from the company's lead candidate, STC-1010, supporting it as a promising therapeutic option for MSS, immune-cold colorectal cancer (CRC)—a major unmet clinical need. In a syngeneic CT26 model, murine STC-1010 significantly inhibits tumor growth and extends survival by 40%. New mechanistic datas reveal expansion of CD4⁺ and CD8⁺ T cells in draining lymph nodes alongside a significant humoral response compared to control, demonstrating coordinated cellular and humoral immune activation in vivo. Other findings show that dendritic cells efficiently capture STC-1010, leading to their activation as demonstrated by transcripto

ENHERTU® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer19.2.2026 08:30:00 CET | Press release

Based on DESTINY-Breast05 phase 3 trial results, which showed ENHERTU reduced the risk of invasive disease recurrence or death by 53% compared to T-DM1 If approved, Daiichi Sankyo and AstraZeneca’s ENHERTU has the potential to become a new standard of care in this early breast cancer setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU® (trastuzumab deruxtecan) as a monotherapy for adult patients with HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant HER2 targeted treatment. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committ

NHOA Energy Advances Delivery of the 51 MWh Broni Battery for Neoen in Italy19.2.2026 08:00:00 CET | Press release

The project confirms NHOA Energy’s long-term commitment to the Italian market NHOA Energy, global provider of utility-scale energy storage systems, is advancing the construction of the Broni Battery, a 10 MW/51 MWh project located in Broni (Pavia), Italy, executed for Neoen, one of the world’s leading independent producers of renewable energy. Civil works at the site are currently underway and advancing on schedule, with commissioning activities planned to start in late spring 2026. Once operational, the Broni Battery will provide essential flexibility services to the Italian electricity system, supporting grid stability and reliability as renewable energy penetration continues to increase. The project represents Neoen’s first battery storage asset in Italy and marks a strategic step in the company’s expansion, as it continues to grow its battery storage portfolio in key markets worldwide to support power system flexibility. The Broni Battery further strengthens NHOA Energy’s long-term

Compass Pathways Announces Pricing of $150 Million Public Offering19.2.2026 02:18:00 CET | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of its public offering of 17,500,000 American Depositary Shares (“ADSs”) at a public offering price of $8.00 per ADS, each representing one ordinary share, and in lieu of ADSs, to certain institutional investors, pre-funded warrants to purchase up to 1,250,000 ADSs at a public offering price of $7.9999 per pre-funded warrant. In addition, Compass Pathways has granted the underwriters a 30-day option to purchase up to an additional 2,812,500 ADSs at the public offering price, less the underwriting discounts and commissions. All of the securities are to be sold by Compass Pathways. The offering is expected to close on or about February 20, 2026, subject to the satisfaction of customary closing conditions. The gross proceeds to Compass Pathways from the offering, before deducting underwriting discounts and commissions and other est

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye